Bristol-Myers, Pfizer stocks rise on blood-thinner patent win - (MarketWatch via NewsPoints Desk)

  • Bristol Myers Squibb and partner Pfizer won a key patent decision after a federal judge in the US ruled in favour of the companies in a dispute over Eliquis, reported MarketWatch.

  • The judge said that products made by Sigmapharm Laboratories, Sunshine Lake Pharma Co., and Unichem Laboratories infringed patents protecting the anticoagulant, which is generically known as apixaban.

  • "While subject to appeal, at present the generic manufacturers currently involved in the case cannot launch their apixaban products until 2031," said a Bristol Myers Squibb spokewoman.

  • She added that "based on settlement agreements reached with other generic manufacturers, we currently expect generic entry could occur after 2026 but before 2031, subject to appeals and future challenges."

  • Bristol Myers Squibb and Pfizer have a profit-sharing agreement on the drug, which generated $2 billion last year.

To read more NewsPoints articles, click here.